{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:35:27Z","timestamp":1793090127591,"version":"4.5.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Viatris Inc"},{"name":"Italian Ministry of University","award":["2022AWB8T4"],"award-info":[{"award-number":["2022AWB8T4"]}]},{"name":"Italian Ministry of University","award":["P2022SE38P_004"],"award-info":[{"award-number":["P2022SE38P_004"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Erectile dysfunction (ED) is a multifactorial condition with psychological, vascular, hormonal, neurological, and systemic risk factors. Four phosphodiesterase-5 inhibitors (PDE5is), sildenafil, tadalafil, vardenafil, and avanafil, have been approved by the United States Food and Drug Administration and the European Medicines Agency for the management of ED.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>While several meta-analyses have assessed the efficacy of PDE5is in the management of ED, none have focused on dose-specific outcomes. Hence, the study was conducted to compare the dose-dependent efficacy and safety of four FDA\/EMA-approved PDE5is in the treatment of ED using on-demand dosages.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive literature search identified randomized, double-blind, placebo-controlled trials. Only on-demand doses of PDE5is were included in the network meta-analysis (NMA), which focused on primary outcomes such as the proportion of participants achieving satisfactory erectile function (EF), defined as an International Index of Erectile Function (IIEF) domain score\u2009&amp;gt;\u200926. A threshold analysis was conducted to evaluate the robustness of treatment recommendations derived from the NMA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 83 studies with 6029 participants (treatment group: 3457 participants; placebo group: 2572 participants) were included. This dose\u2013response network meta-analysis highlighted better efficacy with sildenafil (sildenafil 100\u00a0mg: odds ratio [OR] 9.06, sildenafil 50\u00a0mg: OR 7.90) in improving EF compared to that with placebo, followed by tadalafil (tadalafil 20\u00a0mg: OR 7.13, tadalafil 10\u00a0mg: OR 3.14), vardenafil (vardenafil 10\u00a0mg: OR 7.78), and avanafil (avanafil 200\u00a0mg: OR 3.42, avanafil 100\u00a0mg: OR 1.75). Threshold analysis showed a statistically significant improvement in ED with sildenafil 100\u00a0mg [OR 2.20; 95% confidence interval (CI) 1.78\u20132.63] and 50\u00a0mg (OR 2.10; 95% CI 1.69\u20132.50) compared to placebo. This indicated the robustness of the results, with moderate variations unlikely to alter their comparative ranking within the NMA. The odds of treatment-related adverse events were highest for vardenafil, followed by avanafil and sildenafil, and lowest for tadalafil compared to placebo. However, in some instances, the wide CI showed higher variability and potential uncertainty in effect estimates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PDE5is are highly effective, with sildenafil showing a significantly greater efficacy compared with the other PDE5is.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jsxmed\/qdag176","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T11:44:42Z","timestamp":1779363882000},"source":"Crossref","is-referenced-by-count":4,"title":["A comparative evaluation of on-demand phosphodiesterase-5 inhibitor efficacy in erectile dysfunction treatment: a systematic review and network meta-analysis of double-blind, placebo-controlled, randomized trials"],"prefix":"10.1093","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0595-7165","authenticated-orcid":false,"given":"Andrea","family":"Salonia","sequence":"first","affiliation":[{"name":"Division of Experimental Oncology\/Unit of Urology, Vita-Salute San Raffaele University , Milan 20132 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Bettocchi","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Foggia , Foggia , Puglia (Apulia) 71121,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6560-8605","authenticated-orcid":false,"given":"Arthur","family":"Burnett","sequence":"additional","affiliation":[{"name":"Department of Urology, John Hopkins University , Baltimore , Maryland 21287,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9894-2885","authenticated-orcid":false,"given":"Giovanni","family":"Corona","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Medical Department, Maggiore-Bellaria Hospital , Bologna , Emilia-Romagna 40133,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkel","family":"Fode","sequence":"additional","affiliation":[{"name":"Department of Urology, Copenhagen University Hospital, Herlev and Gentofte Hospital , Herlev , Capital Region 2730,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Hassan","sequence":"additional","affiliation":[{"name":"Department of US Medical Affairs Urology and Eye Care, Viatris Inc. , New York, NY 10001 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suks","family":"Minhas","sequence":"additional","affiliation":[{"name":"Department of Urology, Imperial Healthcare NHS Trust, Charing Cross Hospital , London W6 8RF ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5455-3047","authenticated-orcid":false,"given":"John P","family":"Mulhall","sequence":"additional","affiliation":[{"name":"Department of Urology, Memorial Sloan Kettering Cancer Center , New York, NY 10065 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Sadeghi-Nejad","sequence":"additional","affiliation":[{"name":"Department of Urology and OBG, NYU Grossman School of Medicine , New York, NY 10017 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivani Ohri","family":"Vignesh","sequence":"additional","affiliation":[{"name":"Department of Medical Affair Global TA Excellence Medical Affairs, Viatris , Bengaluru , Karnataka 560103,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Run","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Texas MD Anderson Cancer Center and McGovern Medical School at Houston , Texas 77030-4009 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuele A","family":"Jannini","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome Tor Vergata , Rome 00133 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"2026061513262821800_ref1","author":"EAU-Guidelines on sexual and reproductive health","year":"2025"},{"key":"2026061513262821800_ref2","volume-title":"StatPearls [Internet]","author":"Dhaliwal","year":"2026"},{"key":"2026061513262821800_ref3","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/andr.12683","article-title":"The first-generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue","volume":"7","author":"Zucchi","year":"2019","journal-title":"Andrology."},{"key":"2026061513262821800_ref4","volume-title":"FDA Label Cialis (Tadalafil) Tablets","year":"2017"},{"key":"2026061513262821800_ref5","volume-title":"FDA Label Levitra (Vardenafil Hydrochloride) Tablets","year":"2003"},{"key":"2026061513262821800_ref6","volume-title":"FDA Label Stendra (Avanafil) Tablets","year":"2012"},{"key":"2026061513262821800_ref7","volume-title":"FDA Label Viagra (Sildenafil Citrate) Tablets","year":"1998"},{"issue":"3 Suppl","key":"2026061513262821800_ref8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.urology.2006.05.046","article-title":"Research instruments for the diagnosis and treatment of patients with erectile dysfunction","volume":"68","author":"Rosen","year":"2006","journal-title":"Urology."},{"key":"2026061513262821800_ref9","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/sj.ijir.3901410","article-title":"Inventories for male and female sexual dysfunctions","volume":"18","author":"Corona","year":"2006","journal-title":"Int J Impot Res"},{"key":"2026061513262821800_ref10","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/j.1743-6109.2006.00422.x","article-title":"Development and validation of the quality of erection questionnaire","volume":"4","author":"Porst","year":"2007","journal-title":"J Sex Med"},{"key":"2026061513262821800_ref11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/j.1743-6109.2007.00694.x","article-title":"Evaluating the sexual experience in men: validation of the sexual experience questionnaire","volume":"5","author":"Mulhall","year":"2008","journal-title":"J Sex Med"},{"key":"2026061513262821800_ref12","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s00345-020-03233-9","article-title":"Efficacy and safety of oral phosphodiesterase 5 inhibitors for erectile dysfunction: a network meta-analysis and multicriteria decision analysis","volume":"39","author":"Madeira","year":"2021","journal-title":"World J Urol"},{"key":"2026061513262821800_ref13","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1111\/andr.12255","article-title":"First-generation phosphodiesterase type 5 inhibitors dropout: a comprehensive review and meta-analysis","volume":"4","author":"Corona","year":"2016","journal-title":"Andrology."},{"key":"2026061513262821800_ref14","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.eururo.2015.03.031","article-title":"Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis","volume":"68","author":"Chen","year":"2015","journal-title":"Eur Urol"},{"key":"2026061513262821800_ref15","doi-asserted-by":"publisher","first-page":"650","DOI":"10.7326\/0003-4819-151-9-200911030-00150","article-title":"Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis","volume":"151","author":"Tsertsvadze","year":"2009","journal-title":"Ann Intern Med"},{"key":"2026061513262821800_ref16","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13074","article-title":"Sexual habits of men with ED who take phosphodiesterase 5 inhibitors: a survey conducted in 7 countries","volume":"72","author":"Mulhall","year":"2018","journal-title":"Int J Clin Pract"},{"key":"2026061513262821800_ref17","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"2026061513262821800_ref18","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","article-title":"PRESS peer review of electronic search strategies: 2015 guideline statement","volume":"75","author":"McGowan","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"2026061513262821800_ref19","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/S0090-4295(99)00099-0","article-title":"Diagnostic evaluation of the erectile function domain of the international index of erectile function","volume":"54","author":"Cappelleri","year":"1999","journal-title":"Urology."},{"key":"2026061513262821800_ref20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.urology.2006.05.041","article-title":"Erection hardness: a unifying factor for defining response in the treatment of erectile dysfunction","volume":"68","author":"Mulhall","year":"2006","journal-title":"Urology."},{"key":"2026061513262821800_ref21","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1111\/j.1743-6109.2007.00600.x","article-title":"Validation of the erection hardness score","volume":"4","author":"Mulhall","year":"2007","journal-title":"J Sex Med"},{"key":"2026061513262821800_ref22","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/sj.ijir.3900857","article-title":"The international index of erectile function (IIEF): a state-of-the-science review","volume":"14","author":"Rosen","year":"2002","journal-title":"Int J Impot Res"},{"issue":"3 Suppl","key":"2026061513262821800_ref23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.urology.2006.06.027","article-title":"Erectile function and assessments of erection hardness correlate positively with measures of emotional well-being, sexual satisfaction, and treatment satisfaction in men with erectile dysfunction treated with sildenafil citrate (Viagra)","volume":"68","author":"Montorsi","year":"2006","journal-title":"Urology."},{"key":"2026061513262821800_ref24","volume-title":"Nested Knowledge Features","author":"Nested Knowledge"},{"key":"2026061513262821800_ref25","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ."},{"key":"2026061513262821800_ref26","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1037\/1082-989X.11.2.193","article-title":"Assessing heterogeneity in meta-analysis: Q statistic or I2 index?","volume":"11","author":"Huedo-Medina","year":"2006","journal-title":"Psychol Methods"},{"key":"2026061513262821800_ref27","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/9781119536604.ch11","volume-title":"Undertaking Network Meta-Analyses. Cochrane Handbook for Systematic Reviews of Interventions","author":"Chaimani","year":"2019"},{"key":"2026061513262821800_ref28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13643-017-0473-z","article-title":"Approaches to interpreting and choosing the best treatments in network meta-analyses","volume":"6","author":"Mbuagbaw","year":"2017","journal-title":"Syst Rev"},{"key":"2026061513262821800_ref29","doi-asserted-by":"publisher","first-page":"e024625","DOI":"10.1136\/bmjopen-2018-024625","article-title":"Empirical evaluation of SUCRA-based treatment ranks in network meta-analysis: quantifying robustness using Cohen\u2019s kappa","volume":"9","author":"Daly","year":"2019","journal-title":"BMJ Open"},{"key":"2026061513262821800_ref30","author":"The R Foundation"},{"key":"2026061513262821800_ref31","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.eururo.2011.07.053","article-title":"Minimal clinically important differences in the erectile function domain of the international index of erectile function scale","volume":"60","author":"Rosen","year":"2011","journal-title":"Eur Urol"},{"key":"2026061513262821800_ref32","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/rssa.12341","article-title":"Sensitivity of treatment recommendations to bias in network meta-analysis","volume":"181","author":"Phillippo","year":"2018","journal-title":"J R Stat Soc Ser A Stat Soc"},{"key":"2026061513262821800_ref33","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.3346\/jkms.2017.32.6.1016","article-title":"A randomized, placebo-controlled, double-blind, multi-center therapeutic confirmatory study to evaluate the safety and efficacy of Avanafil in Korean patients with erectile dysfunction","volume":"32","author":"Park","year":"2017","journal-title":"J Korean Med Sci"},{"key":"2026061513262821800_ref34","doi-asserted-by":"publisher","first-page":"100337","DOI":"10.1016\/j.esxm.2021.100337","article-title":"Efficacy and safety of Avanafil in Chinese subjects with erectile dysfunction: a multi-center, randomized, double-blinded, placebo-controlled phase III clinical trial","volume":"9","author":"Jiang","year":"2021","journal-title":"Sex Med"},{"key":"2026061513262821800_ref35","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/j.1743-6109.2004.04029.x","article-title":"Efficacy and safety of on-demand oral tadalafil in the treatment of men with erectile dysfunction in Taiwan: a randomized, double-blind, parallel, placebo-controlled clinical study","volume":"1","author":"Chen","year":"2004","journal-title":"J Sex Med"},{"key":"2026061513262821800_ref36","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/j.1442-2042.2006.01393.x","article-title":"Efficacy and safety of on-demand tadalafil for the treatment of erectile dysfunction in south-east Asian men","volume":"13","author":"Guo","year":"2006","journal-title":"Int J Urol"},{"key":"2026061513262821800_ref37","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1001\/jama.1993.03510010089036","article-title":"Impotence. NIH consensus development panel on impotence","volume":"270","author":"NIH Consensus Conference","year":"1993","journal-title":"JAMA."},{"key":"2026061513262821800_ref38","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.sxmr.2019.06.008","article-title":"Epidemiology update of erectile dysfunction in eight countries with high burden","volume":"8","author":"Goldstein","year":"2020","journal-title":"Sex Med Rev"},{"key":"2026061513262821800_ref39","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/bju.14813","article-title":"The global prevalence of erectile dysfunction: a review","volume":"124","author":"Kessler","year":"2019","journal-title":"BJU Int"},{"key":"2026061513262821800_ref40","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2147\/RRU.S283097","article-title":"The quality of life and economic burden of erectile dysfunction","volume":"13","author":"Elterman","year":"2021","journal-title":"Res Rep Urol"},{"key":"2026061513262821800_ref41","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.sxmr.2017.04.002","article-title":"SM = SM: the interface of systems medicine and sexual medicine for facing non-communicable diseases in a gender-dependent manner","volume":"5","author":"Jannini","year":"2017","journal-title":"Sex Med Rev"},{"key":"2026061513262821800_ref42","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/13685530802468497","article-title":"Why can patients with erectile dysfunction be considered lucky? The association with testosterone deficiency and metabolic syndrome","volume":"11","author":"Corona","year":"2008","journal-title":"Aging Male"},{"key":"2026061513262821800_ref43","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.urology.2021.08.009","article-title":"Erectile dysfunction and treatment: an analysis of associated chronic health conditions","volume":"157","author":"Wright","year":"2021","journal-title":"Urology."},{"key":"2026061513262821800_ref44","first-page":"1488","article-title":"Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study","volume":"44","author":"Ghofrani","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"2026061513262821800_ref45","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.eururo.2013.01.012","article-title":"Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis","volume":"63","author":"Yuan","year":"2013","journal-title":"Eur Urol"},{"key":"2026061513262821800_ref46","first-page":"407","article-title":"Phosphodiesterase-5 (PDE5) inhibitors in the management of erectile dysfunction","volume":"38","author":"Huang","year":"2013","journal-title":"P T"},{"key":"2026061513262821800_ref47","first-page":"99","article-title":"Patient preference and satisfaction in erectile dysfunction therapy: a comparison of the three phosphodiesterase-5 inhibitors sildenafil, vardenafil and tadalafil","volume":"3","author":"Raheem","year":"2009","journal-title":"Patient Prefer Adherence"},{"key":"2026061513262821800_ref48","doi-asserted-by":"publisher","first-page":"5467","DOI":"10.1111\/bph.14920","article-title":"Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease","volume":"177","author":"Tzoumas","year":"2020","journal-title":"Br J Pharmacol"},{"key":"2026061513262821800_ref49","volume-title":"EAU Guidelines on Sexual and Reproductive Health \u2013 Uroweb"},{"key":"2026061513262821800_ref50","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/ijcp.12939","article-title":"Treatment response to sildenafil in men with erectile dysfunction relative to concomitant comorbidities and age","volume":"71","author":"Goldstein","year":"2017","journal-title":"Int J Clin Pract"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/23\/7\/qdag176\/68529461\/qdag176.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/23\/7\/qdag176\/68529461\/qdag176.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T17:26:34Z","timestamp":1781544394000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/doi\/10.1093\/jsxmed\/qdag176\/8708262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jsxmed\/qdag176","relation":{},"ISSN":["1743-6095","1743-6109"],"issn-type":[{"value":"1743-6095","type":"print"},{"value":"1743-6109","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,6,5]]},"article-number":"qdag176"}}